Introduction Welcome back Vitalians and please join us in congratulating the Remedium Bio team for passing the VitaDAO token holder vote with 75.61% voting in favour! This proposal was an assessment of a regenerative medicine biotechnology company, which has developed the only dose adjustable gene therapy platform technology Prometheus™ and is currently advancing multiple assets with uncorrelated risk to Investigational New Drug (IND) approval.
November Longevity Research Newsletter
November Longevity Research Newsletter
November Longevity Research Newsletter
Introduction Welcome back Vitalians and please join us in congratulating the Remedium Bio team for passing the VitaDAO token holder vote with 75.61% voting in favour! This proposal was an assessment of a regenerative medicine biotechnology company, which has developed the only dose adjustable gene therapy platform technology Prometheus™ and is currently advancing multiple assets with uncorrelated risk to Investigational New Drug (IND) approval.